



# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

Date: November 13, 2021

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,


**Subject: Outcome of the Board Meeting held on 13<sup>th</sup> November 2021, Saturday, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Saturday, 13th November 2021 at 11.30 a.m concluded at 12.00 noon. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter and half year ended 30th September, 2021.
2. Limited Review Report from the auditor for the quarter and half year ended 30th September, 2021.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You  
Yours Truly  
For Ajooni Biotech Limited  
  
Swati Vijan  
Company Secretary  
(ACS: 39179)





# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

Date: November 13, 2021

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SYMBOL: AJOONI**


**Sub.: Approval of Un-audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2021.**

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 13/11/2021 at the Registered Office of the company have considered and approved the Audited Financial Statements for the quarter and half year ended 30<sup>th</sup> September, 2021. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter and half year ended on 30<sup>th</sup> September 2021.
2. Limited Review Report from the auditor for the quarter and half year ended on 30<sup>th</sup> September, 2021.

You are requested to kindly take the same on record.


Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited  
  
Jasjit Singh  
Managing Director  
DIN: 01937631



AJOONI BIOTECH LIMITED						
CIN : L85190PB2010PLC040162						
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2021 (In Lakhs)						
PARTICULARS	Quarter Ended				Year Ended	
	30.09.2021	30.06.2021	30.09.2020	Period Ended (UnAudited) 30.09.2021	Period Ended (UnAudited) 30.09.2020	31.03.2021
<b>I Income</b>						
Revenue from operations	1,839.19	1,584.62	1,211.04	3,423.81	2,194.20	5103.88
Other income	0.81	0.92	0.22	1.73	0.73	1.72
<b>Total income from operations</b>	<b>1,840.00</b>	<b>1,585.54</b>	<b>1,211.26</b>	<b>3,425.54</b>	<b>2,194.93</b>	<b>5,105.60</b>
<b>II Expenses</b>						
Cost of Material Consumed	1,562.05	1,342.82	1,059.33	2,904.87	1,874.65	4335.59
Change in Inventories	(15.22)	(1.49)	(16.66)	(16.71)	(20.69)	-34.32
Employee benefit expenses	42.03	38.10	30.43	80.13	62.48	114.78
Finance costs	22.18	13.30	10.36	35.48	20.80	58.40
Depreciation and amortization expenses	28.86	18.93	5.80	47.80	21.30	57.75
Payment to NSF						
Other expenses	154.81	133.08	113.33	287.89	183.94	522.98
<b>Total expenses</b>	<b>1,794.71</b>	<b>1,544.74</b>	<b>1,202.59</b>	<b>3,339.46</b>	<b>2,142.48</b>	<b>5,055.18</b>
<b>III tax</b>	<b>45.29</b>	<b>40.80</b>	<b>8.67</b>	<b>86.08</b>	<b>52.45</b>	<b>50.42</b>
<b>IV Exceptional items</b>						
<b>V Profit/(Loss) before tax</b>	<b>45.29</b>	<b>40.80</b>	<b>8.67</b>	<b>86.08</b>	<b>52.45</b>	<b>50.42</b>
<b>VI Tax expenses</b>						
a) Current tax	11.78	10.50	2.25	22.28	13.6	15.03
b) Deferred tax	1.75	1.05	-	2.80	-	1.91
b) Mat Credit	-	-	-	-	-	-
<b>VII Net Profit/(Loss) for the period/year</b>	<b>35.26</b>	<b>31.35</b>	<b>6.42</b>	<b>66.60</b>	<b>38.85</b>	<b>37.30</b>
<b>VIII Other comprehensive income (net of tax)</b>						
profit or loss:	4.93	-	-	4.93	-	(181)
<b>Total other comprehensive income</b>	<b>4.93</b>	<b>-</b>	<b>-</b>	<b>4.93</b>	<b>-</b>	<b>(181)</b>
<b>IX period/year (VII+VIII)</b>	<b>40.19</b>	<b>31.35</b>	<b>6.42</b>	<b>71.53</b>	<b>38.85</b>	<b>(144.03)</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>1,000.55</b>	<b>1,000.55</b>	<b>840.50</b>	<b>1,000.55</b>	<b>840.50</b>	<b>1,000.55</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>637.51</b>	<b>596.69</b>	<b>755.02</b>	<b>637.51</b>	<b>787.45</b>	<b>564.51</b>
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>						
-Basic	0.35	0.31	0.08	0.67	0.46	0.37
-Diluted	0.35	0.31	0.08	0.67	0.46	0.37

**Notes:**

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.11.2021 after being reviewed by the Audit Committee.
- The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.
- Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited  
  
 Jasbir Singh  
 Managing Director  
 DIN: 01937631

Date: 13/11/2021

Place : Mohali

Statement of Assets and Liabilities  
 For the Year ended on 30th September 2021

PARTICULARS	in Rs.	
	30TH SEPTEMBER 2021	31ST MARCH 2021
<b>I. ASSETS</b>		
<b>(1) Non - Current Assets</b>		
a) Property, Plant and Equipment	61,037,828	51,617,081
b) Financial Assets		
(1) Non-Current Investments	10,787,122	11,482,856
(2) Advances		
c) Deffered Tax Asset	1,745,029	1,465,029
d) Other Non Current Assets	703,514	1,407,030
<b>(2) Current Assets</b>		
a) Inventories	30,490,225	53,762,090
b) Financial Assets		
(1) Cash & Cash Equivalent	1,517,793	2,440,976
(2) Short Term Loans and advances	21,947,573	19,882,931
(3) Trade Receivables	159,714,538	137,117,389
c) Other Current Asset		1,087,547
<b>TOTAL Rs.</b>	<b>287,943,622</b>	<b>280,262,930</b>
<b>II EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
a) Equity Share Capital	100,055,820	100,055,820
b) Other Equity	63,751,226	56,451,410
<b>(2) Non-Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	31,269,941	18,979,313
<b>(3) Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	43,857,734	48,857,260
(2) Trade Payables	46,257,706	54,003,957
b) Other Current Liabilities	1,573,195	411,890
c) Current tax liabilities (Net)	1,178,000	1,503,280
<b>TOTAL Rs.</b>	<b>287,943,622</b>	<b>280,262,930</b>

Date: 13.11.2021  
 Place: Mohali

For Ajooni Biotech Limited  
  
 Jasjot Singh  
 Managing Director (DIN: 01937631)



# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

( A PEER REVIEWED FIRM )

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Ajooni Biotech Limited having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended

30<sup>th</sup> SEPTEMBER 2021 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.  
Chartered Accountants

MOHALI  
CA Konia Madan  
Partner

M. No 547759

Date: 13.11.2021

UDIN : 21547759AAAACW5123

House No. 1122, Sector 71, Mohali

Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com